FMR LLC and Abigail P. Johnson report significant ownership of BRUKER CORP common stock. FMR LLC is listed with 23,296,465.55 shares beneficially owned, representing 15.0% of the class. FMR LLC has 17,974,598.38 shares with sole voting power and 23,296,465.55 shares with sole dispositive power, with no shared voting or dispositive power reported.
Abigail P. Johnson is also reported as a beneficial owner of 23,296,465.55 shares, equal to 15.0% of the class, with sole dispositive power and no voting or shared powers listed. One or more other persons have rights to dividends or sale proceeds tied to these shares, but no single such person holds more than five percent of BRUKER CORP’s outstanding common stock.
Bruker Corporation reported Q2 2026 revenue of $838.5 million, up from $797.4 million, with growth across BSI CALID, BSI NANO, and BEST. Gross profit rose to $416.0 million, but a $134.9 million goodwill impairment and other charges drove a consolidated operating loss of $65.3 million. After interest and other income of $24.6 million, taxes, and $10.9 million of preferred dividends, net loss attributable to common shareholders was $62.9 million, or $(0.41) per share, versus $0.05 earnings a year earlier.
For the first half of 2026, revenue was $1,661.9 million and net loss to common shareholders was $59.4 million. Bruker deployed $81.1 million of consideration (net of cash acquired) on acquisitions, including the remaining 60% of Tofwerk, adding goodwill of $35.4 million and identifiable intangibles (technology $42.7 million, customer relationships $3.5 million, tradename $1.6 million). Total goodwill decreased to $1,429.8 million after impairments of $98.4 million for the CST reporting unit and $36.5 million for the BSB reporting unit. Operating cash flow was a $6.2 million use, compared with $62.5 million use a year earlier; cash, cash equivalents and restricted cash were $189.1 million, and long-term debt was $1,814.7 million. Remaining performance obligations reached $2,775.6 million, and a post‑June 30 reorganization into BIOS, BMID, BSI NANO, and BEST will trigger an interim goodwill impairment analysis in the third quarter of 2026.
Bruker Corporation reported Q2 2026 revenue of $838.5 million, up 5.2% year over year, with organic growth of 2.8% and double‑digit organic bookings growth in its Scientific Instruments segment. BEST revenue rose 11.9% and BSI revenue increased 4.7%, reflecting strength in semiconductor, energy research, and biopharma markets, while U.S. academic demand remained soft.
GAAP results swung to a loss as a non‑cash goodwill impairment charge of $134.9 million drove a GAAP operating loss of $65.3 million and a GAAP diluted loss per share of $(0.41), versus earnings of $0.05 a year earlier. On a non‑GAAP basis, operating income rose to $118.5 million with margin expanding to 14.1%, and non‑GAAP diluted EPS increased to $0.49 from $0.32. For the first half, revenue grew 3.9% to $1,661.9 million, while free cash flow remained negative.
Bruker updated its 2026 outlook only for currency and tax, now expecting revenue of $3.54 to $3.57 billion, implying 3% to 4% growth, and reaffirming non‑GAAP EPS guidance of $2.10 to $2.15, 15% to 17% above 2025, assuming a 27.5% effective non‑GAAP tax rate.
Bruker Corporation declared a quarterly cash dividend of $3.9844 per share on its 6.375% Mandatory Convertible Preferred Stock, Series A. The dividend was declared on July 30, 2026 and is payable on September 1, 2026 to shareholders of record at the close of business on August 15, 2026. This action applies specifically to the company’s outstanding Series A preferred shares and reflects the stated 6.375% dividend rate on that class of stock.
Mark Munch, an executive vice president of Bruker Corp, exercised stock options for 2,000 shares at $22.19 per share and sold 2,000 common shares at $60.25 per share in open-market trades under a Rule 10b5-1 trading plan. After these transactions he holds 128,443 common shares directly and 4,000 stock options exercisable at $22.19 expiring on October 4, 2026.
Security holder Mark R. Munch filed a notice to sell 2,000 shares of BRKR common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on or after July 15, 2026 on NASDAQ, with an estimated aggregate value of $120,500. The shares are to be acquired from the issuer for cash via stock option exercise. Over the prior three months, he sold 2,000 shares for $109,520 on June 15, 2026 and 2,000 shares for $87,800 on May 15, 2026.
BRUKER CORP officer Wolfgang Pusch, President BMID Group, reported his initial beneficial ownership on a Form 3. He holds 10,154 shares of Common Stock, reported as direct ownership.
Bruker Corp executive Mark Munch reported an option exercise and related share sale. He exercised stock options to acquire 2,000 shares of Common Stock at $22.19 per share and on the same day sold 2,000 shares in an open‑market transaction at $54.76 per share.
The filing notes that the sales were made under a pre‑arranged Rule 10b5‑1 trading plan. Following these transactions, Munch directly holds 128,443 shares of Bruker Common Stock.
Bruker, Inc. (BRKR) notice of proposed sale of 2,000 shares of Common Stock via a stock option exercise to the issuer for cash, dated 06/15/2026. The filing lists prior sales by Mark R. Munch of 2,000 shares on 05/15/2026 for $87,800.00 and 2,000 shares on 04/15/2026 for $79,800.00.
The notice describes the proposed sale method as an exercise through Morgan Stanley Smith Barney LLC and records the transaction party as the issuer. This is an affiliate resale notice under standard procedures and the excerpt does not state any proceeds recipient beyond the issuer or broader strategic implications.
Bruker Corporation has filed a shelf registration on Form S-3 to register an unlimited aggregate amount of securities for offer and resale from time to time, including common stock, preferred stock, debt securities, warrants, units, depositary shares, subscription rights and purchase contracts. Selling stockholders may also offer shares pursuant to supplements.
The prospectus states that specific terms, amounts, offering prices and whether proceeds will be received by Bruker or selling holders will be set forth in prospectus supplements; unless a supplement states otherwise, proceeds from sales by selling stockholders will not be received by Bruker.